BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26560358)

  • 1. AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease.
    Katz ML; Tecedor L; Chen Y; Williamson BG; Lysenko E; Wininger FA; Young WM; Johnson GC; Whiting RE; Coates JR; Davidson BL
    Sci Transl Med; 2015 Nov; 7(313):313ra180. PubMed ID: 26560358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extraneuronal pathology in a canine model of CLN2 neuronal ceroid lipofuscinosis after intracerebroventricular gene therapy that delays neurological disease progression.
    Katz ML; Johnson GC; Leach SB; Williamson BG; Coates JR; Whiting REH; Vansteenkiste DP; Whitney MS
    Gene Ther; 2017 Apr; 24(4):215-223. PubMed ID: 28079862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease).
    Katz ML; Coates JR; Sibigtroth CM; Taylor JD; Carpentier M; Young WM; Wininger FA; Kennedy D; Vuillemenot BR; O'Neill CA
    J Neurosci Res; 2014 Nov; 92(11):1591-8. PubMed ID: 24938720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CLN2 Disease (Classic Late Infantile Neuronal Ceroid Lipofuscinosis).
    Kohlschütter A; Schulz A
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():682-8. PubMed ID: 27491216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement therapy delays pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis.
    Whiting RE; Narfström K; Yao G; Pearce JW; Coates JR; Castaner LJ; Jensen CA; Dougherty BN; Vuillemenot BR; Kennedy D; O'Neill CA; Katz ML
    Exp Eye Res; 2014 Aug; 125():164-72. PubMed ID: 24954537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracerebroventricular gene therapy that delays neurological disease progression is associated with selective preservation of retinal ganglion cells in a canine model of CLN2 disease.
    Whiting REH; Jensen CA; Pearce JW; Gillespie LE; Bristow DE; Katz ML
    Exp Eye Res; 2016 May; 146():276-282. PubMed ID: 27039708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifocal retinopathy in Dachshunds with CLN2 neuronal ceroid lipofuscinosis.
    Whiting RE; Pearce JW; Castaner LJ; Jensen CA; Katz RJ; Gilliam DH; Katz ML
    Exp Eye Res; 2015 May; 134():123-32. PubMed ID: 25697710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis.
    Fietz M; AlSayed M; Burke D; Cohen-Pfeffer J; Cooper JD; Dvořáková L; Giugliani R; Izzo E; Jahnová H; Lukacs Z; Mole SE; Noher de Halac I; Pearce DA; Poupetova H; Schulz A; Specchio N; Xin W; Miller N
    Mol Genet Metab; 2016 Sep; 119(1-2):160-7. PubMed ID: 27553878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal implantation of TPP1-transduced stem cells delays retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis.
    Tracy CJ; Whiting RE; Pearce JW; Williamson BG; Vansteenkiste DP; Gillespie LE; Castaner LJ; Bryan JN; Coates JR; Jensen CA; Katz ML
    Exp Eye Res; 2016 Nov; 152():77-87. PubMed ID: 27637672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis.
    Vuillemenot BR; Kennedy D; Cooper JD; Wong AM; Sri S; Doeleman T; Katz ML; Coates JR; Johnson GC; Reed RP; Adams EL; Butt MT; Musson DG; Henshaw J; Keve S; Cahayag R; Tsuruda LS; O'Neill CA
    Mol Genet Metab; 2015 Feb; 114(2):281-93. PubMed ID: 25257657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Basic ApoE-Based Peptide Mediator to Deliver Proteins across the Blood-Brain Barrier: Long-Term Efficacy, Toxicity, and Mechanism.
    Meng Y; Wiseman JA; Nemtsova Y; Moore DF; Guevarra J; Reuhl K; Banks WA; Daneman R; Sleat DE; Lobel P
    Mol Ther; 2017 Jul; 25(7):1531-1543. PubMed ID: 28456380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis.
    Vuillemenot BR; Katz ML; Coates JR; Kennedy D; Tiger P; Kanazono S; Lobel P; Sohar I; Xu S; Cahayag R; Keve S; Koren E; Bunting S; Tsuruda LS; O'Neill CA
    Mol Genet Metab; 2011 Nov; 104(3):325-37. PubMed ID: 21784683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel CLN2/TPP1 mutation in a patient with late infantile neuronal ceroid lipofuscinosis.
    Yu F; Liu XM; Chen YH; Zhang SQ; Wang K
    Neurol Sci; 2015 Oct; 36(10):1917-9. PubMed ID: 26032578
    [No Abstract]   [Full Text] [Related]  

  • 14. Partial genetic suppression of a loss-of-function mutant of the neuronal ceroid lipofuscinosis-associated protease TPP1 in Dictyostelium discoideum.
    Phillips JE; Gomer RH
    Dis Model Mech; 2015 Feb; 8(2):147-56. PubMed ID: 25540127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A zebrafish model of CLN2 disease is deficient in tripeptidyl peptidase 1 and displays progressive neurodegeneration accompanied by a reduction in proliferation.
    Mahmood F; Fu S; Cooke J; Wilson SW; Cooper JD; Russell C
    Brain; 2013 May; 136(Pt 5):1488-507. PubMed ID: 23587805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease.
    Gardner E; Bailey M; Schulz A; Aristorena M; Miller N; Mole SE
    Hum Mutat; 2019 Nov; 40(11):1924-1938. PubMed ID: 31283065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inducible transgenic expression of tripeptidyl peptidase 1 in a mouse model of late-infantile neuronal ceroid lipofuscinosis.
    Nemtsova Y; Wiseman JA; El-Banna M; Lobel P; Sleat DE
    PLoS One; 2018; 13(2):e0192286. PubMed ID: 29408933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Untargeted Metabolite Profiling of Cerebrospinal Fluid Uncovers Biomarkers for Severity of Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2, Batten Disease).
    Sindelar M; Dyke JP; Deeb RS; Sondhi D; Kaminsky SM; Kosofsky BE; Ballon DJ; Crystal RG; Gross SS
    Sci Rep; 2018 Oct; 8(1):15229. PubMed ID: 30323181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis.
    Passini MA; Dodge JC; Bu J; Yang W; Zhao Q; Sondhi D; Hackett NR; Kaminsky SM; Mao Q; Shihabuddin LS; Cheng SH; Sleat DE; Stewart GR; Davidson BL; Lobel P; Crystal RG
    J Neurosci; 2006 Feb; 26(5):1334-42. PubMed ID: 16452657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene symbol: TPP1. Disease: Neuronal Ceroid Lipofuscinosis, late infantile.
    Kohan R; Muller VJ; Fietz MJ; Cismondi AI; Oller Ramírez AM; Halac IN
    Hum Genet; 2008 Jun; 123(5):553. PubMed ID: 20960655
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.